Neurotherapeutics

Appendix 4C – Q3 FY23 Quarterly Cash Flow Report

Retrieved on: 
Wednesday, May 10, 2023

MELBOURNE, Australia and SAN FRANCISCO, May 10, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st March 2023 (Q3 FY23).

Key Points: 
  • MELBOURNE, Australia and SAN FRANCISCO, May 10, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st March 2023 (Q3 FY23).
  • “The Phase 2 trial is gaining momentum with active recruitment in five countries, including the United States.
  • We were pleased that an independent study was published providing further evidence that ATH434 has potential to be neuroprotective in humans.”
    The Company’s cash position on 31 March 2023 was A$21.9M with operating cash outflows of A$4M.
  • In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates included in item 6.1 of the Appendix 4C incorporates directors’ fees, consulting fees, remuneration and superannuation at commercial rates.

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Retrieved on: 
Thursday, March 23, 2023

BOTHELL, Wash., March 23, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2022, and reviewed recent pipeline and business updates.

Key Points: 
  • BOTHELL, Wash., March 23, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2022, and reviewed recent pipeline and business updates.
  • We are targeting to complete enrollment of the LIFT-AD trial in mid-2023 and to have topline data in early 2024.
  • Fosgonimeton (ATH-1017) - Small molecule designed to enhance the activity of the HGF/MET system with the potential to protect and repair neuronal networks.
  • As of year-end 2022, greater than 85% of participants who have completed either study have elected to enroll in the OLEX trial.

Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model

Retrieved on: 
Monday, January 30, 2023

The publication, entitled “ATH434 Rescues Pre‑motor Hyposmia in a Mouse Model of Parkinsonism” assessed the impact of ATH434 on motor and non-motor deficits in mice with genetically induced Parkinson’s disease1.

Key Points: 
  • The publication, entitled “ATH434 Rescues Pre‑motor Hyposmia in a Mouse Model of Parkinsonism” assessed the impact of ATH434 on motor and non-motor deficits in mice with genetically induced Parkinson’s disease1.
  • The study found that ATH434 prevented a loss of smell in the younger mice and rescued it in older mice.
  • These data support other studies indicating that ATH434 has a beneficial effect on the motor and non-motor symptoms in animal models of PD.
  • The demonstration of efficacy in yet another model of Parkinson’s disease adds to the weight of evidence supporting the potential of ATH434 to address the underlying pathology of Parkinson’s disease and related disorders.”

Athira Pharma Provides 2023 Pipeline Outlook

Retrieved on: 
Thursday, January 5, 2023

BOTHELL, Wash., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided an update on its pipeline development programs and outlook for 2023.

Key Points: 
  • Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects
    BOTHELL, Wash., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided an update on its pipeline development programs and outlook for 2023.
  • This includes our recently published preclinical results in the peer-reviewed journal, Neurotherapeutics, supporting the potential of fosgonimeton,” stated Mark Litton, Ph.D., President and Chief Executive Officer of Athira Pharma.
  • Athira enrolled 28 patients in the exploratory Phase 2 SHAPE study of fosgonimeton in participants with Parkinson’s disease dementia or Dementia with Lewy bodies.
  • ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS.

Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics

Retrieved on: 
Wednesday, December 21, 2022

BOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data demonstrating the neuroprotective, neurotrophic and procognitive effects of fosgonimeton (ATH-1017) in preclinical models.

Key Points: 
  • BOTHELL, Wash., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data demonstrating the neuroprotective, neurotrophic and procognitive effects of fosgonimeton (ATH-1017) in preclinical models.
  • The article titled, “Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia,” was published online on December 20, 2022 in the peer-reviewed journal, Neurotherapeutics.
  • "This publication adds to the growing body of preclinical evidence demonstrating that enhancing the HGF/MET neurotrophic system with fosgonimeton may have therapeutic benefit for dementia and other neurodegenerative diseases,” said Kevin Church, Ph.D., Executive Vice President, Research of Athira Pharma.
  • “These data demonstrate that treatment with fosgonimeton or its active metabolite, fosgo-AM, protects cortical neurons challenged with neurotoxic insults that mimic critical aspects of neurodegeneration.

NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference

Retrieved on: 
Thursday, September 29, 2022

CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it will participate in Cantor Fitzgerald's Cantor Neurology and Psychiatry Conference scheduled to take place October 6-7, 2022 in San Francisco.

Key Points: 
  • Alon Ben-Noon, NeuroSense's CEO, will be a panelist on the conference's ALS panel titled: New Treatment Paradigm with More MoAs On the Way?
  • Prof. Shefner is a board certified in neurologist by the American Board of Psychiatry and Neurology, and he specializes in ALS and neuromuscular disorders.
  • Cantor Fitzgerald's Neurology & Psychiatry Conference, led by Dr. Charles Duncan, Cantor's Managing Director and central nervous system (CNS) expert analyst, will feature a day of interactive discussions, one-on-ones, and panel presentations.
  • The conference will be focused on neuro-innovators, who are engaged in development and commercialization of therapeutics for high unmet need indications in the neurology and psychiatry industries.

Therapeutic Solutions International Recruits Dr. Donald Banerji to Scientific Advisory Board

Retrieved on: 
Wednesday, May 25, 2022

Therapeutic Solutions International announced today the appointment of Dr. Donald Banerji to the Companys Scientific Advisory Board.

Key Points: 
  • Therapeutic Solutions International announced today the appointment of Dr. Donald Banerji to the Companys Scientific Advisory Board.
  • I am pleased to welcome Dr. Banerji to our Scientific Advisory Board.
  • Success in the area of regenerative medicine requires deep knowledge of the complicated scientific, biological and clinical issues associated with developing a living drug.
  • Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.

NI Research Publishes Annual Review of Alzheimer's Therapeutics

Retrieved on: 
Thursday, September 12, 2019

SAN DIEGO, Sep. 12, 2019 /PRNewswire/ -- NI Research is pleased to announce that the September/October issue of NeuroPerspectivehas been released.

Key Points: 
  • SAN DIEGO, Sep. 12, 2019 /PRNewswire/ -- NI Research is pleased to announce that the September/October issue of NeuroPerspectivehas been released.
  • It features ourcomprehensive annual review of the Alzheimer'sspace, including an assessment of the current conceptual trends vis-a-vis pathophysiology and therapeutic targets.
  • NI Research is the premier provider of independent appraisals of the neurotherapeutics area.
  • NI Research also provides strategic and licensing consultation ('Second Opinion') to companies ranging from the largest major pharma companies to early-stage startups.

The National Research Council of Canada and Aspect Biosystems work toward new ways to deliver therapeutics to the brain, the holy grail of biopharmaceutical sciences

Retrieved on: 
Wednesday, February 13, 2019

Unfortunately, this barrier also prevents the majority of therapeutics from reaching their target, which means there are few effective treatments for brain diseases.

Key Points: 
  • Unfortunately, this barrier also prevents the majority of therapeutics from reaching their target, which means there are few effective treatments for brain diseases.
  • The NRC's acquisition of the RX1TM Bioprinter was made possible through funding from the Build in Canada Innovation Program.
  • Research Officer, Therapeutics Beyond Brain Barriers program, National Research Council of Canada
    "We are excited to begin this multidisciplinary collaboration that marries the expertise of the NRC and Aspect Biosystems.
  • We will thereby enable drug developers to more efficiently and effectively develop life-changing neurotherapeutics for a wide range of brain diseases and disorders."